Fatty Liver Disease: Nonalchoholic

Green Clock Hours: 1.50

Nonalcoholic fatty liver disease (NAFLD) has a widespread prevalence in the U.S., with incidence rates increasing in parallel with the rise in obesity rates (Sharma & John, 2021b). Treatment for NAFLD is distinct from other types of chronic liver disease in that the primary therapy is lifestyle modification with an emphasis on weight loss. Currently, the Food and Drug Administration (FDA) has not approved any pharmacological treatments for NAFLD, but some medications have led to improvements in cardiometabolic comorbidities. Many cases of early-stage NAFLD will go undiagnosed due to a lack of screening, but disease progression can be prevented if found early. This course will review the risk factors for developing NAFLD and best practices for the diagnosis, monitoring, and management of the disease. 



Read More

$32.00

Course Description

Nonalcoholic fatty liver disease (NAFLD) has a widespread prevalence in the U.S., with incidence rates increasing in parallel with the rise in obesity rates (Sharma & John, 2021b). Treatment for NAFLD is distinct from other types of chronic liver disease in that the primary therapy is lifestyle modification with an emphasis on weight loss. Currently, the Food and Drug Administration (FDA) has not approved any pharmacological treatments for NAFLD, but some medications have led to improvements in cardiometabolic comorbidities. Many cases of early-stage NAFLD will go undiagnosed due to a lack of screening, but disease progression can be prevented if found early. This course will review the risk factors for developing NAFLD and best practices for the diagnosis, monitoring, and management of the disease. 



Only $249
Want Unlimited Access?
The Academy All Access Subscription provides 1-click enrollment into 1,450+ courses for one low price.
Only $249